1278250-15-9

Basic information

• Product Name: 5-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine
• Synonyms: 5-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine
• CAS NO: 1278250-15-9
• Molecular Weight: 291.122
• Mol File: 1278250-15-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine(1278250-15-9)
• EPA Substance Registry System: 5-bromo-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridine(1278250-15-9)

Safety Data

• Hazardous Substances Data: 1278250-15-9(Hazardous Substances Data)

Upstream product

• 1278250-13-7 2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone 
• 1278250-14-8 2-(4-bromopyridin-2-yl)-1-(4-fluorophenyl)ethanone oxime 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 22282-99-1 4-bromo-2-methylpyridine 

Downstream Products

• 1278652-52-0 methyl 3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]benzoate 
• 1310405-48-1 2-(4-fluorophenyl)-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine 
• 1310405-46-9 N-Cyclopropyl-3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]-benzamide 
• 1310405-41-4 3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]-2,N-dimethylbenzamide 
• 1278250-02-4 1-{3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl}prop-2-yn-1-ol 
• 1278250-16-0 3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]benzaldehyde 
• 1278652-44-0 {3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl}methanol 
• 1278652-46-2 1-{3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl}ethanol 
• 1278652-45-1 2-{3-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-5-yl]phenyl}propan-2-ol 

Relevant articles and documents

5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF

Compounds of formula (I): in which: R1 represents a phenyl group or naphthyl group, optionally substituted by one or more atoms or groups chosen, independently of one another, from: halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, (C1-C6)thioalkyl, —S(O)(C1-C6)alkyl, —S(O)2(C1-C6)alkyl, hydroxyl, hydroxy(C1-C6)alkylene, CHO, COOH, (C1-C6)alkoxy(C1-C6)alkyleneoxy, NRaRb, CONRaRb, SO2NRaRb, NRcCORd, OC(O)NRaRb, OCO(C1-C6)alkyl, NRcC(O)ORe or NRcSO2Re; X represents from 1 to 4 substituents which are identical to or different from one another and which are chosen from hydrogen, halogen, (C1-C6)alkyl or (C1-C6)alkoxy, it being possible for the (C1-C6)alkyl to be optionally substituted by one or more groups chosen from a halogen, (C1-C6)alkoxy or hydroxyl; R2 and R3 represent, independently of one another, a hydrogen atom, a (C1-C6)alkyl group optionally substituted by an Rf group, or a CHO or COOH group; X and R3 can together form, with the carbon atoms which carry them, a carbocycle of 5 to 7 carbon atoms; R4 represents a hydrogen atom or a (C1-C6)alkyl group; Ra and Rb represent, independently of one another, a hydrogen atom or a (C1-C6)alkyl, aryl(C1-C6)alkylene or aryl group; or Ra and Rb together form, with the nitrogen atom which carries them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group, this group being optionally substituted by a (C1-C6)alkyl, aryl or aryl(C1-C6)alkylene group; Rc and Rd represent, independently of one another, a hydrogen atom or a (C1-C6)alkyl, aryl(C1-C6)alkylene or aryl group; or Rc and Rd together form a (C2-C5)alkylene group; Re represents a (C1-C6)alkyl, aryl(C1-C6)alkylene or aryl group; or Rc and Re together form a (C2-C5)alkylene group; Rf represents a hydroxyl, oxo, CHO or COOH group, in the form of the base or of an addition salt with an acid. Therapeutic use and synthetic process.

DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS

The invention relates to a formula (I), in which R is a hydrogen or halogen atom or a (C1-C6)alkyl group; X is one or more substituents selected from a hydrogen or halogen atom, a (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkoxy, cyano, hydroxy, or hydroxy(C1-C6)alkyl group; Y is a hydrogen or halogen atom or a (C1-C6)alkyl group; R1 is an NR2R3 or OR4 group; R2 and R3 independently are a hydrogen atom, a (C1-C6)alkyl, hydroxy(C1-C6)alkyl or oxo(C1-C6)alkyl group or R2 and R3, together with the nitrogen atom supporting the same, form a heterocycle optionally substituted by a (C1-C6)alkyl, hydroxy or oxo group; and R4 is a (C1-C6)alkyl, hydroxy(C1-C6)alkyl, or oxo(C1-C6)alkyl group, in the base or acid addition salt state. Said formula can be used therapeutically for treating or preventing diseases linked to the nuclear receptors Nurr-1, also known as NR4A2, NOT, TINUR, RNR-1, and HZF3.